Zacks Investment Research on MSN
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases
Merck MRK announced that it has initiated three separate phase IIb studies evaluating its investigational TL1A inhibitor, ...
Merck (MRK) closed at $80.40 in the latest trading session, marking a -1.36% move from the prior day. This change lagged the S&P 500's 0.44% gain on the day. On the other hand, the Dow registered a ...
Merck (MRK) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts ...
Zacks Investment Research on MSN
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
Merck’s MRK shares have risen almost 13% in the past week as Pfizer’s PFE landmark deal with the Trump administration to ...
Merck MRK announced that the FDA has approved its immuno-oncology drug Keytruda for yet another indication. Keytruda, an anti-PD-1 therapy, is now approved for the adjuvant treatment of patients with ...
Merck (MRK) has recently wrapped up another month of trading, sparking renewed discussion about its longer-term performance.
Merck & Co., Inc. (NYSE:MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a deal valued at over $3 billion, aiming to strengthen its drug pipeline. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback